Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, ottobre 20
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
NeuroSense Therapeutics Ltd
NRSN
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$2.67
N/A
Ult. Agg.: Oct 20, 11:39 AM
$2.89
0.23
8.44%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Privacy Manager
PRO
Perché si muove?:
NeuroSense shares are trading lower. The company announced filing of a pate...
NeuroSense Therapeutics Financials
NeuroSense Therapeutics (NRSN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
NeuroSense Therapeutics H1 EPS $(2.10) up From $(3.70) YoY
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(2.10). This is a 43.24 percent increase over losses of $(3.70) per share from the same period last year.
Benzinga Newsdesk
PRO
NeuroSense Therapeutics FY EPS $(0.44) Misses $(0.35) Estimate
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.35) by 25.71 percent.
Benzinga Newsdesk
PRO
NeuroSense Therapeutics FY 2024 GAAP EPS $(0.54) Beats $(0.60) Estimate
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.60) by 10 percent. This is a 27.03 percent increase over losses of $(0.74) per share
Benzinga Newsdesk
PRO
NeuroSense Therapeutics 9-Month EPS $(0.48) Up From $(0.55) YoY
Benzinga Newsdesk
PRO
NeuroSense Therapeutics Q1 EPS $(0.35) Misses $(0.20) Estimate
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.20) by 75 percent. This is a 6.06 percent decrease over losses of $(0.33) per share
Benzinga Newsdesk
PRO
NeuroSense Therapeutics Q4 EPS $(0.16) Beats $(0.23) Estimate
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.23) by 30.43 percent. This is a 40.74 percent increase over losses of $(0.27) per
Benzinga Newsdesk
